Tbio CHD2 Chromodomain-helicase-DNA-binding protein 2

Protein Summary

Description

DNA-binding helicase that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3. Involved in myogenesis via interaction with MYOD1: binds to myogenic gene regulatory sequences and mediates incorporation of histone H3.3 prior to the onset of myogenic gene expression, promoting their expression (By similarity). The CHD family of proteins is characterized by the presence of chromo (chromatin organization modifier) domains and SNF2-related helicase/ATPase domains. CHD genes alter gene expression possibly by modification of chromatin structure thus altering access of the transcriptional apparatus to its chromosomal DNA template. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Uniprot Accession IDs

• O14647
• C6G482
• Q96IP5
• CHD-2

Gene Name

• CHD2

Ensembl ID

• ENST00000394196
• ENSP00000377747
• ENSG00000173575
• ENST00000420239
• ENSP00000406581
• ENST00000626874
• ENSP00000486629

Symbol

• EEOC

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
molecular function	1
protein domain	0.99
transcription factor binding site profile	0.93
transcription factor perturbation	0.91
transcription factor	0.73

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 10.6   (req: < 5)

Gene RIFs: 26   (req: <= 3)

Antibodies: 175   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 10.6   (req: >= 5)

Gene RIFs: 26   (req: > 3)

Antibodies: 175   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 9

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0